GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (OTCPK:HNGZY) » Definitions » Capex-to-Revenue

HNGZY (Hangzhou Tigermed Consulting Co) Capex-to-Revenue : 0.04 (As of Sep. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

Hangzhou Tigermed Consulting Co's Capital Expenditure for the three months ended in Sep. 2024 was $-10.71 Mil. Its Revenue for the three months ended in Sep. 2024 was $241.57 Mil.

Hence, Hangzhou Tigermed Consulting Co's Capex-to-Revenue for the three months ended in Sep. 2024 was 0.04.


Hangzhou Tigermed Consulting Co Capex-to-Revenue Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co Capex-to-Revenue Chart

Hangzhou Tigermed Consulting Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.05 0.07 0.06 0.04

Hangzhou Tigermed Consulting Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.06 0.07 0.05 0.04

Competitive Comparison of Hangzhou Tigermed Consulting Co's Capex-to-Revenue

For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hangzhou Tigermed Consulting Co's Capex-to-Revenue Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hangzhou Tigermed Consulting Co's Capex-to-Revenue falls into.



Hangzhou Tigermed Consulting Co Capex-to-Revenue Calculation

Hangzhou Tigermed Consulting Co's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-43.942) / 1034.15
=0.04

Hangzhou Tigermed Consulting Co's Capex-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-10.712) / 241.573
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hangzhou Tigermed Consulting Co  (OTCPK:HNGZY) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


Hangzhou Tigermed Consulting Co Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hangzhou Tigermed Consulting Co Business Description

Traded in Other Exchanges
Address
Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.